meningococcal A, C, Y, W conjugate vaccine

A quadrivalent **conjugate vaccine** against invasive disease caused by *Neisseria meningitidis* serogroups A, C, W, and Y. The vaccine contains purified capsular polysaccharides from each of the four serogroups, individually conjugated to a carrier protein (such as **tetanus toxoid** in MenQuadfi or CRM197 in Menveo). It induces immunity by stimulating the production of specific antibodies against these bacterial serogroups and prevents meningococcal disease. Indicated for active immunization in various age groups (from 6 weeks or 2 months, depending on the specific brand) for **prevention of meningococcal disease**[1][2][5].

Brand names

MenQuadfiMenveoMenactra

Other names

MenACWY conjugate vaccinequadrivalent meningococcal conjugate vaccine